Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

M. Wilhelm, Scott; Dumas, Jacques; Adnane, Lila; Lynch, Mark; A. Carter, Christopher; Schütz, Gunnar; Thierauch, Karl‐Heinz; Zopf, Dieter

doi:10.1002/ijc.25864

Public

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Published in International Journal of Cancer • Dec 17, 2010

Authors:

Scott M. Wilhelm

Jacques Dumas

Lila Adnane

Abstract

Angiogenesis, a critical driver of tumor development, is controlled by interconnected signaling pathways. Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 play crucial roles in the biology of normal and tumor ...

Subject

Regorafenib

Cancer research

Receptor tyrosine kinase

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!